share_log

海通国际：维持华润医药(03320)“优于大市”评级 目标价8.12港元

Haitong International: Maintaining China Resources Pharmaceutical's (03320) “Better Than Market” Rating Target Price of HK$8.12

Zhitong Finance ·  Mar 27 05:05

The Zhitong Finance App learned that Haitong International released a research report stating that it maintains China Resources Pharmaceuticals (03320)'s “superior to the market” rating, with a target price of HK$8.12. It is estimated that 2024-26 will achieve revenue of 2710/2993/329.8 billion yuan, with corresponding growth rates of 10.8%/10.4%/10.2%, respectively; net profit to mother of 42.87/47.49/ 5.241 billion yuan, respectively, with corresponding growth rates of 11.2%/10.8%/10.4%, respectively. The bank believes that the Group will actively expand its business layout through epitaxial mergers and acquisitions, while continuously integrating internal resources to achieve collaboration, and that the equity incentive plans for its subsidiaries are implemented in an orderly manner, which will help the Group achieve sustainable and steady growth.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment